|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0930 AUD | -7.00% |
|
+3.33% | +9.41% |
EPS & Dividend: Neurizon Therapeutics Limited
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0046 | -0.004235 | -0.00539 | -0.0194 | -0.0207 | -0.034 |
| Distribution rate | - | - | - | - | - | - |
| Reference price 2 | 0.1550 | 0.0910 | 0.0700 | 0.0750 | 0.1950 | 0.1600 |
| Nbr of stocks (in thousands) | 3,02,021 | 3,16,730 | 3,16,912 | 3,47,475 | 4,45,024 | 4,92,306 |
| Announcement Date | 18/09/20 | 18/08/21 | 26/08/22 | 31/08/23 | 30/08/24 | 25/08/25 |
1AUD in Million2AUD
Estimates
Upcoming events: Neurizon Therapeutics Limited
| 26/02/2026 | Q2 2026 Earnings Release (Projected) |
| 27/08/2026 | Q4 2026 Earnings Release (Projected) |
| 04/03/2027 | Q2 2027 Earnings Release (Projected) |
| 02/09/2027 | Q4 2027 Earnings Release (Projected) |
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | ||
|---|---|---|---|---|---|---|
 | 0.55% | 0.62% | 46.93x | 35.43x | 15.27x | |
| 2.15% | 2.21% | 21.8x | 7.38x | 6.43x | |
| 2.93% | 3.08% | 62.39x | 21401.34x | 7.4x | |
| 2.82% | 2.9% | 18.44x | 6.45x | 4.63x | |
| 2.65% | 2.76% | 15.75x | 5.49x | 5.05x | |
| 1.69% | 1.78% | 30.26x | 6.67x | 5.44x | |
| 2.98% | 2.92% | 20.34x | 6.32x | 5.75x | |
| 3.65% | 3.9% | 13.96x | 6.02x | 4.82x | |
| 2.49% | 2.61% | 29.86x | 22.87x | 6.92x | |
| Average | 2.43% | 2.53% | 28.86x | 2,388.66x | 6.86x | |
| Weighted average by Cap. | 2.06% | 2.15% | 32.61x | 2,363.69x | 8.36x |
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition